Abstract
Tabulated are compounds that are being or have been evaluated in non-small cell lung cancer. The compounds are listed by class, and under each class, they are listed in the order of their phase of clinical development, with those in the latest phase being listed first. If relevant the phase of development in lung cancer is also noted. If the disease site for compounds in phase II or phase III development is not specified, it implies non-small cell lung cancer. The most common toxicities for a particular compound are listed only if there are published data are available. The commonly accepted abbreviations are used. Thoracic Oncology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Disclosure: The authors declare no conflicts of interest. Address for correspondence: George R. Simon, MD, Thoracic Oncology Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, E-mail: george.simon@fccc.edu Copyright © 2009 2009 by the International Association for the Study of Lung Cancer ISSN: 1556-0864/09/0411-1046 Santa Monica Supplement Journal of Thoracic Oncology • Volume 4, Number 11, Supplement 3, November 2009
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
